Going beyond Polycomb: EZH2 functions in prostate cancer
- 4 August 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 40 (39), 5788-5798
- https://doi.org/10.1038/s41388-021-01982-4
Abstract
The Polycomb group (PcG) protein Enhancer of Zeste Homolog 2 (EZH2) is one of the three core subunits of the Polycomb Repressive Complex 2 (PRC2). It harbors histone methyltransferase activity (MTase) that specifically catalyze histone 3 lysine 27 (H3K27) methylation on target gene promoters. As such, PRC2 are epigenetic silencers that play important roles in cellular identity and embryonic stem cell maintenance. In the past two decades, mounting evidence supports EZH2 mutations and/or over-expression in a wide array of hematological cancers and solid tumors, including prostate cancer. Further, EZH2 is among the most upregulated genes in neuroendocrine prostate cancers, which become abundant due to the clinical use of high-affinity androgen receptor pathway inhibitors. While numerous studies have reported epigenetic functions of EZH2 that inhibit tumor suppressor genes and promote tumorigenesis, discordance between EZH2 and H3K27 methylation has been reported. Further, enzymatic EZH2 inhibitors have shown limited efficacy in prostate cancer, warranting a more comprehensive understanding of EZH2 functions. Here we first review how canonical functions of EZH2 as a histone MTase are regulated and describe the various mechanisms of PRC2 recruitment to the chromatin. We further outline non-histone substrates of EZH2 and discuss post-translational modifications to EZH2 itself that may affect substrate preference. Lastly, we summarize non-canonical functions of EZH2, beyond its MTase activity and/or PRC2, as a transcriptional cofactor and discuss prospects of its therapeutic targeting in prostate cancer.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA180995, T32CA09560)
- U.S. Department of Defense (W81XWH-17-1-0578)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
This publication has 162 references indexed in Scilit:
- EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase ComplexMolecular Cell, 2012
- PCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family ComplexesMolecular Cell, 2012
- Histone Methylation by PRC2 Is Inhibited by Active Chromatin MarksMolecular Cell, 2011
- Nucleosome-Interacting Proteins Regulated by DNA and Histone MethylationCell, 2010
- Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic TransformationCancer Cell, 2010
- TNF/p38α/Polycomb Signaling to Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of Muscle RegenerationCell Stem Cell, 2010
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAsCell, 2007
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004
- The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3Current Opinion in Genetics & Development, 2004